SCHEMBL6085579

SCHEMBL6085579

CCN(CC)c1ccc(C(=O)Nc2ccc(-c3n[nH]cc3-c3nc4cc(S(=O)(=O)CC)ccc4o3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CETP P11597 1/20 0.52
HDAC6 Q9UBN7 2/20 0.51
MAPT P10636 14/20 0.47
RXFP1 Q9HBX9 4/20 0.47
THRB P10828 2/20 0.47
CYP1A2 P05177 1/20 0.45
AHR P35869 1/20 0.45
UTRN P46939 1/20 0.45
TP53 P04637 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
MMP13 P45452 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085349 0.91 CETP (0.53) CETPHDAC6MAPTRXFP1THRB
SCHEMBL6085971 0.90 MAPT (0.59) CETPHDAC6MAPTRXFP1THRB
SCHEMBL6085118 0.89 CETP (0.51) CETPHDAC6MAPTRXFP1THRB
SCHEMBL6085683 0.85 CETP (0.52) CETPMAPTCYP1A2TP53SMN1; SMN2
SCHEMBL6085287 0.82 CETP (0.56) CETPHDAC6MAPTCYP1A2AHR
SCHEMBL6086190 0.81 MAPT (0.49) HDAC6MAPTRXFP1THRBTP53
SCHEMBL6086537 0.80 CETP (0.55) CETPHDAC6MAPTTHRBCYP1A2
SCHEMBL6086812 0.79 CETP (0.50) CETPHDAC6MAPTCYP1A2AHR
SCHEMBL6084333 0.79 CETP (0.56) CETPHDAC6MAPTRXFP1THRB
SCHEMBL6087087 0.79 CETP (0.45) CETPHDAC6MAPTRXFP1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 CETP 4875/4885HDAC6 533/4885MAPT 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.